Clinical trials: ANCA-Associated Vasculitis
ANCA Associated Systemic Vasculitis, Wegener's Granulomatosis
Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
A comparison of intermittent pulsed cyclophosphamide to daily oral cyclophosphamide for the treatment of ANCA-associated systemic vasculitides with kidney involvement. Performed by the European Vasculitis Study group.
- Conditions
- ANCA Associated Systemic Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
- Trial name
- NCT00430105
- Testing
- cyclophosphamide
- Volunteers
- 160 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
ANCA Associated Vasculitis
Multicenter Cohort Study of AAV in Hunan of China
This study aimed to explore the incidence of Anti-neutrophil cytoplasmic antibody (ANCA）-associated vasculitis (AAV) progression and its association with adverse consequences.
- Trial name
- NCT05315141
- Testing
- No Intervention
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xiangya Hospital of Central South University
Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as…
- Conditions
- Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
- Trial name
- ROSY-F (NCT07444567)
- Testing
- Benralizumab
- Where
- 47 sites in United States, Argentina and 12 more
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or…
- Trial name
- NCT00315380
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 700 people
- Sponsor
- University of Pennsylvania
Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV)
IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy
This is an exploratory trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a single dose of IMPT-514, an autologous, anti-CD19/CD20 CAR T therapy, administered as an intravenous (IV)…
- Conditions
- Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM)
- Trial name
- NCT06462144
- Testing
- IMPT-514 CART Cell Injection
- Where
- 3 sites in China
- Volunteers
- 3 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
IgA Nephropathy, Kidney Transplant Recipients
MYTP01 for Immune-Mediated Diseases
The goal of this study is to evaluate whether MYTP01, a traditional Chinese herbal formula developed by clinical experts with the assistance of artificial intelligence (AI), is effective and safe as an additional treatment for…
- Conditions
- IgA Nephropathy, Kidney Transplant Recipients, Lupus Nephritis, Primary Membranous Nephropathy
- Trial name
- NCT07901764
- Testing
- MYTP01
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Zhejiang Provincial People's Hospital
ANCA Associated Vasculitis
Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis
ANCA vasculitis is a pauci-immune systemic small vessel vasculitis. The anti-neutrophilic cytoplasmic antibodies (ANCA) are pathogenic and cause disease by activating neutrophils which damage blood vessels.
- Trial name
- NCT03906227
- Testing
- ENUMERATION OF CD5+ B Cells
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of North Carolina, Chapel Hill
ANCA Associated Vasculitis (AAV)
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
The primary aim is to study the efficacy of treatment with BDB-001 Injection to induce remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with…
- Trial name
- NCT07168161
- Testing
- BDB-001 injection, Cyclophosphamide, Rituximab
- Where
- 65 sites in China
- Volunteers
- 300 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
Toxicity of anti-IL-5
- Conditions
- Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis
- Trial name
- NCT00266565
- Testing
- Mepolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
ANCA Associated Vasculitis (AAV)
Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
The goal of this clinical trial is to learn if avacopan in combination with short-term (4 weeks) reduced-dose glucocorticoid and rituximab works to treat patients with newly-onset ANCA-associated vasculitis.
- Trial name
- ARRIA (NCT06611696)
- Testing
- Avacopan, prednisolone and rituximab, Prednisolone and rituximab
- Where
- 22 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Chiba University
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Sjogren's Syndrome (SS), Inflammatory Myopathy
- Trial name
- NCT07236801
- Testing
- YTS109 cell
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
- Trial name
- NCT07388277
- Testing
- CC-97540, Lymphodepletion Chemotherapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
ANCA-IgG-positive ANCA Associated Vasculitis
Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis
The goal of this phase I/II clinical trial is to investigate anti-CD 19 chimeric antigen receptor T cell (CAR-T cell) therapy in patients with antineutrophil cytoplasmic antibodies (ANCA) immunoglobulin (IgG) positive ANCA…
- Trial name
- IDEAL (NCT06590545)
- Testing
- KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy
- Volunteers
- 8 people
- Sponsor
- David Simon
ANCA Associated Vasculitis, Cardiovascular Diseases
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
ANCA-associated vasculitis is an autoimmune disease that causes damage to blood vessels. This leads to organ damage with the number of organs affected and the severity of damage varying significantly between patients.
- Conditions
- ANCA Associated Vasculitis, Cardiovascular Diseases, Kidney Diseases
- Trial name
- SPARVASC (NCT05630612)
- Testing
- Sparsentan
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- University of Edinburgh
SLE, Systemic Sclerosis
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with active SLE, SSc, AAV, IIM, NMOSD, MS…
- Conditions
- SLE, Systemic Sclerosis, IIM, NMOSD
- Trial name
- NCT06775912
- Testing
- RD06-05 CART Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Glomerulonephritis Acute
Urinary T Lymphocytes Predict Renal Flares in Patients With Inactive ANCA-associated Glomerulonephritis
Urinary CD4+ and CD8+ T lymphocytes may predict renal flares in patients with inactive ANCA-associated vasculitis and thus serve as early non-invasive biomarkers.
- Trial name
- PRE-FLARED (NCT04428398)
- Testing
- Analysis of urine samples with flow cytometry
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Charite University, Berlin, Germany
Inflammation, Vasculitis
Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis
This study will collect fluid and tissue samples from the bronchi (air passages to the lungs) of patients with Wegener's granulomatosis for laboratory examination.
- Conditions
- Inflammation, Vasculitis, Wegener's Granulomatosis
- Trial name
- NCT00001541
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
ANCA Associated Vasculitis (AAV), Polyangiitis (GPA)
Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
The PREP-ANCA study seeks to establish a more personalized treatment strategy for ANCA-associated vasculitides by assessing the efficacy of pre-emptive rituximab administration upon ANCA repositivity in preventing relapses in…
- Conditions
- ANCA Associated Vasculitis (AAV), Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
- Trial name
- PREP-ANCA (NCT07451847)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ANCA Associated Vasculitis
Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis
This is a prospective observational study to determine the frequency and magnitude of Cytomegalovirus (CMV) reactivation in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) in the acute…
- Trial name
- REACTIVAS (NCT04916704)
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis
Rituximab Vasculitis Maintenance Study
Rituximab is now established as an effective drug for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis following major European and US trials reported in 2010. After a time, its effect wears off and the disease can return.
- Conditions
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
- Trial name
- RITAZAREM (NCT01697267)
- Testing
- Rituximab, Azathioprine
- Where
- 38 sites in United States, Australia and 8 more
- Volunteers
- 188 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust